Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
BIIB
Stock Latest News
The Fly
Biogen receives EC approval for Zurzuvae
8h ago
BIIB
Premium
The Fly
C4 Therapeutics upgraded to Overweight from Equal Weight at Stephens
3d ago
BIIB
CCCC
Premium
The Fly
Brookline sees potential upside to outlook for C4 Therapeutics after Biogen news
13d ago
BIIB
CCCC
Premium
Ratings
Biogen’s Strategic Focus on Lupus Innovations and Pipeline Diversification Earns Buy Rating
14d ago
BIIB
Premium
Ratings
Biogen’s Strategic Positioning and Potential Leadership in the Lupus Treatment Market
14d ago
BIIB
Premium
The Fly
C4 Therapeutics announces Biogen had its IND for BIIB142 accepted by FDA
14d ago
BIIB
CCCC
Premium
Ratings
Biogen’s Stable Near-Term Outlook with Promising Long-Term Growth in Immunology Pipeline
14d ago
BIIB
Premium
Ratings
Biogen’s Competitive Edge: FDA Approval of Leqembi IQLIK Boosts Buy Rating
14d ago
BIIB
Premium
Ratings
Biogen’s Hold Rating: Balancing Long-Term Lupus Potential with Near-Term Alzheimer’s Focus
14d ago
BIIB
Premium
The Fly
Eisai, Biogen initiate rolling BLA to FDA for LEQEMBI
15d ago
BIIB
Premium
The Fly
Early notable gainers among liquid option names on September 2nd
16d ago
PEP
TPL
Premium
The Fly
Stoke, Biogen announce data from open-label extension studies of zorevunersen
16d ago
BIIB
STOK
Premium
The Fly
Biogen, Stoke presents data from Phase 1/2a, OLE studies of zorevunersen
16d ago
BIIB
STOK
Premium
Ratings
Cautious Outlook for Biogen Amid New Developments and Competitive Pressures
16d ago
BIIB
Premium
The Fly
Eisai, Biogen announce FDA approval for Leqembi Iqlik BLA
19d ago
BIIB
Premium
The Fly
UK’s MHRA approves Biogen’s Zurzuvae for postnatal depression
22d ago
BIIB
Premium
The Fly
Biogen, Stoke Therapeutics present data from studies of zorevunersen
24d ago
BIIB
STOK
Premium
The Fly
Eisai and Biogen launch Leqembi in Austria, Germany
24d ago
BIIB
Premium
Company Announcements
Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights
27d ago
BIIB
Premium
Company Announcements
Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy
27d ago
BIIB
Premium
Company Announcements
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment?
27d ago
BIIB
Premium
Company Announcements
Biogen’s Promising Phase 3 Trial: Felzartamab for Kidney Transplant Rejection
28d ago
BIIB
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
